New York, New York (PRWEB) February 24, 2013
Actos lawsuits continue to move forward in the federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana. According to a Scheduling Order dated February 19, 2013, the Court has established a Pilot Bellwether Program, which sets up a stream-lined selection process for a minimum of two Pilot Bellwether trials. The Order stipulates that the litigation’s first Pilot Bellwether trial will begin on January 27, 2014, while the second will commence on April 14, 2014. Attorneys for both sides have been directed to nominate five Actos lawsuits each to participate in the Pilot Bellwether Discovery Pool by April 1, 2013.* (In re: Actos Product Liability Litigation, MDL No. 2299)
“The bellwether trials will provide valuable insight into how juries might weigh similar Actos claims. We look forward to this process getting underway,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to individuals who may have been harmed by the medication.
Actos Bladder Cancer Lawsuits
Actos, known generically as pioglitazone, is approved as a treatment for type 2 diabetes. The U.S. Food & Drug Administration (FDA) ordered Takeda Pharmaceuticals to add new warnings to the Actos label in June 2011, after a study found that long-term use of the drug increased the risk for bladder cancer.* Since then, hundreds of people have filed Actos bladder cancer lawsuits alleging long-term use of the drug caused them to develop the disease.
The nation’s first trial involving an Actos bladder cancer lawsuit is now underway in Los Angeles Superior Court. According to a recent report from Bloomberg.com, court filings in that case show Takeda Pharmaceuticals secretly surveyed a dozen doctors in 2003 to see if they would use a diabetes drug with their patients that carried a warning about the potential for bladder cancer. Plaintiff’s attorneys assert the survey found that “a bladder cancer warning would destroy the sales of Takeda’s most important drug.”**(Cooper v. Takeda Pharmaceuticals America, Inc., CGC-12-518535, California Superior Court (Los Angeles))
After the FDA mandated the Actos label change in June 2011, a number of additional studies confirmed the link between long-term use of the drug and bladder cancer. Most recently, a study published in the British Diabetic Association journal, “Diabetic Medicine,” found that the risk of bladder cancer was significantly higher in patients using Actos compared with control groups.****
Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb10461720.htm.
Copyright©2012 Vocus, Inc.
All rights reserved